Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider directly owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.96, for a total value of $314,400.00.
• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.

Kestra Medical Technologies Stock Up 4.5%

KMTS stock opened at $19.93 on Friday. The firm has a market cap of $1.16 billion, a PE ratio of -5.03 and a beta of 0.83. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The company has a fifty day simple moving average of $20.71 and a 200 day simple moving average of $22.87. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The business’s quarterly revenue was up 62.7% compared to the same quarter last year. Sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KMTS. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. The Goldman Sachs Group reduced their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $27.40.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies in the 4th quarter valued at approximately $31,000. Russell Investments Group Ltd. grew its holdings in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Kestra Medical Technologies during the 3rd quarter worth approximately $48,000. BNP Paribas Financial Markets increased its position in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new position in shares of Kestra Medical Technologies in the fourth quarter valued at $72,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.